News Release
June 28, 2024
EA Pharma Co., Ltd.
Ensho Therapeutics, Inc.

Worldwide License Agreement for EA1080, Oral Selective α4β7 Integrin Antagonist,Signed between EA Pharma and Ensho Therapeutics
Ensho Acquired Rights to Develop and Commercialize EA1080 and Portfolio of Other Oral Selective α4β7 Integrin Antagonists in All Territories
Excluding Japan, China, Hong Kong, Macau, South Korea, Taiwan and ASEANEA Pharma Co., Ltd. (Head Office, Chuo-ku, Tokyo, Japan; President, Hidenori Yabune; “EA Pharma”)
and Ensho Therapeutics, Inc.（Head Office, Morris Plains, New Jersey; Founder, President and Chief
Executive Officer; Neena Bitritto-Garg; “Ensho”） announced today that the two companies havesigned a worldwide exclusive license agreement for the rights to develop, manufacture andcommercialize novel oral inflammatory bowel disease treatments EA1080 and a portfolio of other oral
selectiveα4β7 integrin antagonists for the global market excluding Japan, China, Hong Kong, Macau,
South Korea, Taiwan and ASEAN.
Under the terms of the license agreement, in exchange for full commercialization rights in its territory,
Ensho will conduct global clinical studies for EA1080, in collaboration with EA Pharma. EA Pharma will
receive from Ensho payments on achievement of certain development, regulatory, and commercial
milestones, and tiered royalties up to a low double digit percentage of net sales for EA1080.
Inflammatory bowel disease (IBD) includes ulcerative colitis (UC) and Crohn’s disease, and ischaracterized by inflammation in the gut mucosa which results in abdominal pain, diarrhea, and bloodystools. In many cases, patients may experience remission, but ultimately relapse, which results in anoverall decline in quality of life. The mechanism of onset of IBD remains unknown. In Japan, IBD isconsidered a “designated intractable disease” by the Ministry of Health, Labour and Welfare. In 2019, thenumber of patients registered in Japan with UC and Crohn’s disease were nearly 220,000 and 70,000,
respectively, with prevalence increasing in recent years.1)

In IBD, lymphocytes and other inflammatory cells excessively surround and invade the gut mucosa,
mediated by binding of integrins expressed on the surface of inflammatory cells to adhesion molecules,
such as MAdCAM-1, that are excessively expressed on endothelial cells in the gut mucosa. EA1080 isan orally-available small molecule antagonist of α4β7 integrin. EA1080 can selectively inhibit α4β7integrin cell adhesion mediated by binding to MAdCAM-1, suppressing invasion of lymphocytes into thegut mucosa and quelling inflammation.
“EA1080 is a novel orally-available small molecular α4β7 integrin antagonist created based on our
original and unique drug discovery platform. We expect that the collaboration with Ensho, which is basedin the United States and has strengths in the immunology and inflammatory disease area, will synergize
the knowledge of both companies to accelerate the global development of EA1080 to provide a newtreatment option for patients with IBD,” said Hidenori Yabune, President of EA Pharma.
“Ensho is thrilled to acquire this portfolio of oral, highly selective α4β7 integrin antagonists, led by
EA1080, that have been refined through years of impeccable research by the EA Pharma team,” stated
Neena Bitritto-Garg, CFA, Founder, President, and Chief Executive Officer of Ensho. “We believe thesecompounds could be transformational for patients suffering with IBD, as selective α4β7 antagonists
have been proven to be safe and effective, but the need for oral agents remains.

Our clinicaldevelopment strategy is already set, and we plan to advance EA1080 into Phase 2 clinical developmentin the first half of 2025 so that we may deliver new solutions to patients expeditiously.”Media Inquiries
EA Pharma Co., Ltd.
Corporate Communication Dept.
TEL： +81(0)80-4176-5206

Ensho Therapeutiｃｓ, Inc.
Investor and Media Relations
Email：info@enshorx.com

１）“Basic treatment guidance for patients with ulcerative colitis” (revised March 2020), Research groupfor intractable inflammatory bowel diseases, Research project on rare and intractable diseases,
Health and Labour Sciences Research Grants

More Information
１． About EA Pharma
EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd. for gastrointestinal disease area, was established in April
2016 by integration of the gastrointestinal business unit with more than 60 year’s history of the Eisai Groupand the gastrointestinal business unit of the Ajinomoto Group having amino acid as its business core. EAPharma Co., Ltd., is a gastrointestinal specialty pharmaceutical company with a full value chain covering
R&D, production & logistics and sales & marketing. For further information on EA Pharma Co., Ltd., please
visit https://www.eapharma.co.jp/

２．About Ensho Therapeutics, Inc
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on
developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial
focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7for inflammatory bowel disease (IBD), a mechanism already validated by a commercially availableantibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd.
focused on gastrointestinal disease.

Ensho is preparing to enter Phase 2 clinical trials in IBD with

EA1080, the lead asset in the company’s pipeline. For additional information on Ensho Therapeutics,Inc., please visit www.enshorx.com.
３． Forward-looking statements
This Website contains forward-looking statements that involve risks, uncertainties, and assumptions. Ifrisks or uncertainties ever materialize or the assumptions prove incorrect, our actual results may differ
from those expressed or implied by such forward-looking statements. All statements other thanstatements of historical facts could be deemed forward-looking, including, but not limited to, any
statement of the plans, strategies, and objectives of management for future operations, including but notlimited to our clinical development and commercialization plans; any projections of financial information;
any statements about historical results that may suggest trends for our business; any statements ofexpectation or belief regarding future events, potential markets or market size, technology developments,
our product pipeline, clinical data, results or practices or the implications thereof, enforceability of ourintellectual property rights, competitive strengths or our position within the industry; and any statementsof assumptions underlying any of the items mentioned.